GS
KYTX icon

Gilead Sciences’s Kyverna Therapeutics KYTX Stock Holding History

Gilead Sciences’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$35.6M Hold
4,126,119
– – 1.68% 5
2025
Q4 		$38.8M Hold
4,126,119
– – 2% 5
2025
Q3 		$24.8M Hold
4,126,119
– – 1.38% 7
2025
Q2 		$12.7M Hold
4,126,119
– – 0.99% 7
2025
Q1 		$7.96M Hold
4,126,119
– – 0.67% 6
2024
Q4 		$15.4M Buy
+4,126,119
New +$19.8M 0.99% 6

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Gilead Sciences's KYTX Position: Q1 2026 in Review

Gilead Sciences held its Kyverna Therapeutics (KYTX) position steady in Q1 2026 at 4,126,119 shares worth $35.6M. The position accounts for 1.68% of the portfolio, ranked #5.

Gilead Sciences first reported a position in KYTX in Q4 2024 and has held it in 6 quarters since. The position peaked at $38.8M in Q4 2025. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • Gilead Sciences held 4,126,119 shares of Kyverna Therapeutics worth $35.6M as of Q1 2026.
  • Gilead Sciences left its Kyverna Therapeutics share count unchanged in Q1 2026.
  • Kyverna Therapeutics made up 1.68% of Gilead Sciences's portfolio in Q1 2026, its #5 holding.
  • Gilead Sciences first reported a position in Kyverna Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Gilead Sciences's Kyverna Therapeutics position peaked at $38.8M in Q4 2025.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on Gilead Sciences's 13F filing for Q1 2026, filed 8 May 2026.